CEO Massimiliano Colella delayed introducing the company’s soft tissue surgery system in the U.S. by a year but says the improved robot that is hitting the market now was worth the wait.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results